초록

Nucleic acids encoding factor XΔ analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg 179 are provided.

대표청구항 ▼

1. A recombinant nucleic acid comprising a nucleic acid segment encoding a factor XΔ analogue that (i) comprises a factor X amino acid sequence in which amino acids Arg180 to Arg234 of SEQ ID NO:44 are deleted, and (ii) has a modification in the region between Gly173 and Arg179 of SEQ ID NO:44, the

1. A recombinant nucleic acid comprising a nucleic acid segment encoding a factor XΔ analogue that (i) comprises a factor X amino acid sequence in which amino acids Arg180 to Arg234 of SEQ ID NO:44 are deleted, and (ii) has a modification in the region between Gly173 and Arg179 of SEQ ID NO:44, the modification resulting in a processing site for a protease that does not naturally cleave between Gly173 and Arg179 of SEQ ID NO:44.2. The nucleic acid of claim 1, wherein the modification of the factor XΔ analogue encoded by the nucleic acid is at least one amino acid exchange in the region.3. The nucleic acid of claim 1, wherein the factor XΔ analogue encoded by the nucleic acid comprises a factor X sequence in which amino acids Gly 173 to Arg179 and residue 235 of SEQ ID NO:44 have the sequence Gly173-R6-R5-R4-R3-R2-Arg179/R1(235), and whereina) R1 is an amino acid selected from the group consisting of Val, Ser, Thr, Ile and Ala; b) R2 is an amino acid selected from the group consisting of Glu, Thr, Pro, Gly, Lys and Arg; c) R3 is an amino acid selected from the group consisting of Leu, Phe, Lys, Met, Gln, Glu, Ser, Val, Arg and Pro; d) R4 is an amino acid selected from the group consisting of Thr, Asp, Asn, Ile, Ser, Met, Pro, Arg and Lys; e) R5 is an amino acid selected from the group consisting of Asn, Lys, Ser, Glu, Gln, Ala, His and Arg; and f) R6 is an amino acid selected from the group consisting of Asp, Phe, Thr, Arg, Leu and Ser. 4. The nucleic acid of claim 1, wherein the modification of the factor XΔ analogue encoded by the nucleic acid results in a processing site for a protease selected from the group consisting of an endoprotease, a serine protease and a derivative of these proteases.5. The nucleic acid of claim 4, wherein the modification of the factor XΔ analogue encoded by the nucleic acid results in a processing site for an endoprotease selected from the group consisting of kexin/Kex2, furin/PACE, PC1/PC3, PC2, PC4, PACE 4 and LPC/PC7, or a serine protease selected from the group consisting of factor IIa, factor VIIa, factor IXa, factor XIIa, factor XIa, factor Xa and kallikrein.6. The nucleic acid of claim 1, wherein the modification of the factor XΔ analogue encoded by the nucleic acid permits activation of an inactive, single-chain factor XΔ analogue polypeptide into a double-chain, active factor Xa analogue form.7. The nucleic acid of claim 1, wherein the factor XΔ analogue encoded by the nucleic acid A factor XΔ analogue has a further modification at Lys 370 and/or within a segment extending from Arg469 to Lys488 of SEQ ID NO:44.8. The nucleic acid of claim 7, wherein the further modification of the factor XΔ analogue encoded by the nucleic acid is located at Arg469 and/or Gly470 of SEQ ID NO:44.9. The nucleic acid of claim 7, wherein the further modification of the factor XΔ analogue encoded by the nucleic acid is selected from the group consisting of a mutation, a deletion and an insertion, and is located between amino acid positions Arg469 and Ser476 of SEQ ID NO:44.10. The nucleic acid of claim 1, wherein the further modification of the factor XΔ analogue encoded by the nucleic acid prevents the β-peptide from being cleaved from the XΔ analogue, the β-peptide extending from Gly470 to Lys488 of SEQ ID NO:44.11. The nucleic acid of claim 7, wherein the factor XΔ analogue encoded by the nucleic acid terminates at Arg469.12. The nucleic acid of claim 1, wherein the modification of the factor XΔ analogue encoded by the nucleic acid permits an in vitro activation of the factor XΔ analogue to an active factor XΔ analogue.13. The nucleic acid of claim 12, wherein the modification of the factor XΔ analogue encoded by the nucleic acid permits in vitro activation of the factor XΔ analogue by a protease selected from the group consisting of an endoprotease, a serine protease, and a derivative of these proteases.14. The nucleic acid of claim 13, wherein the modification of the factor XΔ analogue encoded by the nucleic acid permits in vitro activation of the factor XΔ analogue by an endoprotease selected from the group consisting of kexin/Kex2/furin/PACE, PC1/PC3, PC2, PC4, PACE 4, LPC/PC7, or a serine protease selected from the group consisting of factor IIa, factor VIIa, factor IXa, factor XIIa, factor XIa, factor Xa and kallikrein.15. The nucleic acid of claim 1, wherein the factor XΔ analogue encoded by the nucleic acid comprises an intact β-peptide, which extends from Gly470 to Lys488 of SEQ ID NO:44.16. A vector comprising the nucleic acid of claim 1.17. A cell that comprises the vector of claim 16.